Upper limb loss alters individuals’ private and professional life. Prosthetic devices are thus a solution to supply the missing upper limb segments. Nevertheless, commercial prostheses are often unaffordable, or inaccessible, to underprivileged individuals (e.g., no health insurance, low incomes, warzone). Among potential affordable alternatives, additive manufacturing, commonly “3D printing”, has been increasingly employed. This technology offers higher availability and accessibility, and can produce complex geometrical and highly customized products, which are essential features for prostheses manufacturing. Therefore, this study aims to portray an overview of reliable open-source upper limb 3D-printed prostheses currently available. We thus searched the scientific literature and online repositories hosting 3D-printable designs. We extracted data relative to mechanical and kinematic properties, 3D printing process and efficacy for each device. We found six studies implementing open-source 3DP upper limb prostheses and twenty-five open-source designs from online databases meeting selection criteria. Devices’ technical specifications were not systematically reported. In conclusion, though open-source 3D-printed upper limb prostheses can perform some functional tasks and grasps, and are widely employed to supply limb differences, further research is mandatory to validate their usage and to prove their clinical efficacy. More guidelines are required to unify contributions from private makers and non-governmental organizations with scientific groups.

As 3D printing technology expands rapidly in medical disciplines, the accuracy evaluation of 3D-printed medical models is required. However, no established guidelines to assess the dimensional error of anatomical models exist. This study aims to evaluate the dimensional accuracy of medical models 3D-printed using a hospital-based Fused Deposition Modeling (FDM) 3D printer. Two dissected cadaveric right hands were marked with Titanium Kirshner wires to identify landmarks on the heads and bases of all metacarpals and proximal and middle phalanges. Both hands were scanned using a Cone Beam Computed Tomography scanner. Image post-processing and segmentation were performed on 3D Slicer software. Hand models were 3D-printed using a professional hospital-based FDM 3D printer. Manual measurements of all landmarks marked on both pairs of cadaveric and 3D-printed hands were taken by two independent observers using a digital caliper. The Mean Absolute Difference (MAD) and Mean Dimensional Error (MDE) were calculated. Our results showed an acceptable level of dimensional accuracy. The overall study’s MAD was 0.32 mm (±0.34), and its MDE was 1.03% (±0.83). These values fall within the recommended range of errors. A high level of dimensional accuracy of the 3D-printed anatomical models was achieved, suggesting their reliability and suitability for medical applications.

Rebound pain (RP) remains a challenge in ambulatory surgery, characterized by severe pain upon resolution of a peripheral nerve block (PNB). Intravenous (IV) administration of Dexamethasone (DEXA) potentiates PNB analgesic effect and reduces RP incidence although preventive effective dose remains undetermined. This retrospective analysis evaluates the preventive effect of IV DEXA on RP in outpatients undergoing upper limb surgery under axillary block. DEXA was divided into high (HD > 0.1 mg/kg) or low (LD < 0.1 mg/kg) doses. RP was defined as severe pain (NRS ≥ 7/10) within 24 h of PNB resolution. DEXA HD and LD patients were matched with control patients without DEXA (n = 55) from a previous randomized controlled study. Records of 118 DEXA patients were analyzed (DEXA dose ranged from 0.05 to 0.12 mg/kg). Intraoperative IV DEXA was associated with a significant reduction of the pain felt when PNB wore off as well as to a significant reduction of RP incidence (n = 27/118, 23% vs. 47% in controls, p = 0.002) with no effect related to the dose administered (p = 0.053). Our results support the administration of intraoperative DEXA as a preventive measure to reduce the occurrence of RP.